The content on this site is intended for healthcare professionals only
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
9 Apr 2021
Cemiplimab plus ipilimumab for advanced NSCLC
Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea
7 Apr 2021
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small ...
Dr Erminia Massarelli - City of Hope, Duarte, USA
1 Apr 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
29 Mar 2021
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 inserti...
Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passa...
29 Mar 2021
Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC i...
Prof Andrea Filippi - University of Pavia, Pavia, Italy
26 Mar 2021
OncoAlert and ecancer weekly roundup for March 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (ES)
Dr Giuseppe Giaccone, Dr Marina Garassino
2 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (IT)
Dr Giuseppe Giaccone, Dr Marina Garassino
2 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE)
Dr Giuseppe Giaccone, Dr Marina Garassino
2 Mar 2021
Managing the treatment of NSCLC patients during the COVID-19 pandemic (FR)
Dr Giuseppe Giaccone, Dr Marina Garassino
2 Mar 2021
Reducing the risk of contracting COVID-19 in patients with NSCLC (IT)
Dr Giuseppe Giaccone, Dr Neal Navani, Professor Eric Lim
2 Mar 2021
